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Abstract
Background: Sustained exposure of pancreatic b cells to an increase in saturated fatty acids induces pleiotropic effects on b-
cell function, including a reduction in stimulus-induced insulin secretion. The objective of this study was to investigate the
effects of chronic over supply of palmitate upon glucose- and amino acid-stimulated insulin secretion (GSIS and AASIS,
respectively) and autocrine-dependent insulin signalling with particular focus on the importance of ceramide, ERK and
CaMKII signalling.
Principal Findings: GSIS and AASIS were both stimulated by .7-fold resulting in autocrine-dependent activation of protein
kinase B (PKB, also known as Akt). Insulin release was dependent upon nutrient-induced activation of calcium/calmodulin-
dependent protein kinase II (CaMKII) and extracellular signal-regulated kinase (ERK) as their pharmacological inhibition
suppressed GSIS/AASIS significantly. Chronic (48 h, 0.4 mM) palmitate treatment blunted glucose/AA-induced activation of
CaMKII and ERK and caused a concomitant reduction (,75%) in GSIS/AASIS and autocrine-dependent activation of PKB. This
inhibition could not be attributed to enhanced mitochondrial fatty acid uptake/oxidation or ceramide synthesis, which were
unaffected by palmitate. In contrast, diacylglycerol synthesis was elevated suggesting increased palmitate esterification
rather than oxidation may contribute to impaired stimulus-secretion coupling. Consistent with this, 2-bromopalmitate, a
non-oxidisable palmitate analogue, inhibited GSIS as effectively as palmitate.
Conclusions: Our results exclude changes in ceramide content or mitochondrial fatty acid handling as factors initiating
palmitate-induced defects in insulin release from MIN6 b cells, but suggest that reduced CaMKII and ERK activation
associated with palmitate overload may contribute to impaired stimulus-induced insulin secretion.
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Introduction
Hyperlipidemia is one of a cluster of abnormalities associated
with the metabolic syndrome, which not only promotes insulin
resistance, but results in the dysfunction of numerous cellular
responses in tissues such as skeletal muscle [1], heart [2], liver [3],
adipose [4] and the pancreas [5]. In the pancreas, for example, it
has been demonstrated that during the pre-diabetic and diabetic
states, there is an increase in intracellular fatty acids [6] that
desensitise pancreatic beta cells to glucose [7]. An important
consequence of this reduced glucose ‘‘sensing’’ capacity is a
reduction in glucose-stimulated insulin secretion (GSIS), which
contributes to the impaired glucose homeostasis associated with
the diabetic state.
Fatty acids are thought to play an essential role in GSIS
augmenting the glucose-induced secretion of insulin [8,9]. During
the fasting state, fatty acids are free in the cytosol of beta cells, and,
under these circumstances, are channelled into mitochondria for
b-oxidation and generation of ATP [10] and do not promote any
detectable increase in insulin secretion. However, upon feeding,
the rise in blood glucose not only promotes insulin release from
beta cells by a mechanism involving the inactivation (closure) of
plasma membrane K
+
ATP channels, but glucose will also
contribute to metabolic anaplerosis. Citrate produced in the
mitochondria from glucose metabolism will form malonyl-CoA in
the cytosol [11,12], which prevents b-oxidation by inhibiting
carnitine palmitoyltransferase (CPT-1), thereby allowing an
increase in long chain fatty acids which can stimulate insulin
secretion. Although the precise mechanism is unknown it is
thought that long chain fatty acids can either modulate
intracellular targets that stimulate insulin release [13,14] or form
complex lipids, such as diacylglycerol (DAG), that interact with
insulin granule proteins leading to granule fusion with the
membrane [15]. In addition, the presence of free fatty acids,
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aqueous phase, has been suggested to activate the fatty acid G-
protein coupled receptor (GPR40). Activation of GPR40 causes an
increase in intracellular Ca
2+, which is thought to be induced via
activation of the Gaq-phospholipase C pathway. The increase in
free cytosolic Ca
2+ plays a crucial role in stimulating insulin
secretion [14].
Although important for beta cell function, sustained increases in
fatty acid availability and influx, as occur in response to high fat
feeding [6], can induce both dysfunction [7] and death of beta cells
[16] and thereby contribute to the pathogenesis of diabetes
mellitus. Sustained exposure of pancreatic beta cells to fatty acids,
such as palmitate, has been linked to a loss in GSIS and increased
apoptosis [7,17–20]. What is less well understood is the
mechanism underpinning the lipotoxic effects of palmitate.
Analysis of mice lacking GPR40 indicate that although important
in mounting acute responses to fatty acid supply the receptor is
unlikely to contribute to pancreatic dysfunction induced in
response to sustained increases in fatty acid availability [14].
While there is no compelling evidence implicating other fatty acid
receptors or transporters an increase in fatty acid provision has
been suggested to disrupt the glucose-fatty acid cycle by inhibition
of pyruvate dehydrogenase, which switches fuel consumption from
glucose to fatty acid oxidation [18,21]. Fatty acids may also induce
much greater oxidation by increasing the expression of CPT-1
[22] whilst decreasing that of acetyl CoA carboxylase [23]. This
exaggerated fatty acid oxidation may promote beta cell insensi-
tivity to glucose resulting in a concomitant reduction in GSIS,
which may also be underpinned by defects in the regulation or
expression of transcription factors, such as PDX-1 [24], or indeed
that of the insulin gene itself [25]. In many cell types increased
provision of fatty acids has been linked to enhanced intracellular
synthesis and accumulation of ceramide, a sphingolipid that can be
generated de novo from saturated fatty acids (e.g. palmitate) via the
seine palmitoyl transferase (SPT) pathway. Ceramide has been
implicated strongly in cell apoptosis and in the pathogenesis of
insulin resistance and there is evidence in the literature suggesting
that it may be an effector molecule mediating palmitate-induced
beta cell dysfunction [26,27] and beta cell death [6].
Here we show that sustained exposure of pancreatic MIN6 beta
cells to palmitate results in a substantial loss in insulin secretion in
response to glucose or amino acid provision. This fatty acid-
induced impairment in insulin secretion blunts autocrine signalling
by the hormone, but, unlike in other cell types, has no detectable
effect on PKB-directed insulin signalling in response to exoge-
nously supplied hormone. Furthermore, we demonstrate that the
palmitate-induced reduction in insulin secretion cannot be
attributed to ceramide action, but may be due, in part, to a loss
in nutrient-induced CaMKII and ERK signalling which normally
supports the stimulus-dependent secretion of insulin.
Results
Palmitate induces a loss in glucose- and amino acid-
stimulated insulin secretion and induces apoptosis in
MIN6 b cells
Insulin release from pancreatic b cells is normally negligible in
the presence of fasting blood glucose levels (i.e. ,3–4 mM).
However, in response to an increase in extracellular glucose (as
occurs during the post absorptive phase when it may rise by 2–4
fold, i.e. 7–16 mM) or indeed in response to increased amino acid
provision, secretion of insulin is enhanced significantly [28]. This
glucose- and amino acid-dependent response is illustrated in
Figure 1A, which shows a significant increase (up to 7.5-fold) in
insulin secretion when MIN6 b cells were incubated in media
containing 16 mM glucose or a 3 mM glucose/10 mM leucine
and glutamine mix (shown previously to stimulate insulin secretion
independently of glucose metabolism [29]). Irrespective of the
stimulus used, this nutrient-dependent increase in insulin secretion
was significantly blunted when MIN6 b cells were preincubated
with palmitate (0.4 mM) for a period of 48 h (Figure 1A) falling by
,75% when expressed as a net change (Figure 1B). Intriguingly,
even in the absence of a nutrient stimulus we observed a significant
reduction in basal insulin secretion indicating that palmitate over
supply may also target the secretory process that operates in
response to a sub-threshold glucose (3 mM) stimulus.
Given that palmitate is known to induce apoptosis of b cells it is
plausible that the loss in GSIS may be related to a reduction in
MIN6 cell number. However, analysis of adherent cell numbers
based on DAPI staining did not reveal any significant changes in
control or palmitate-treated cell populations (Figure 2A and 2B)
and, in separate experiments, we could not detect any additional
effect upon cell viability of subjecting palmitate-treated MIN6 cells
to a glucose or amino acid stimulus suggesting that cells were able
to tolerate the combind stress of palmitate exposure and energy
stimulation (Figure 2C). Nonetheless, it is noteworthy that
palmitate treatment induces a 2-fold increase in caspase 3/7
activity (a proapoptotic marker) in MIN6 cells (Figure 2B),
suggesting that whilst apoptosis had been initiated by the fatty
acid this had not yet translated to a reduction in cell number over
the 48 h incubation period being studied. However, it is
noteworthy that in preliminary experiments analysis of cell
number following 60 h of treatment with palmitate had revealed
a significant decline in cell survival; an observation that we had
used to help to inform our choice of using a shorter palmitate
incubation period for the studies reported in this paper (data not
shown).
The loss in GSIS cannot be attributed to ceramide action
Palmitate-driven ceramide synthesis has been shown to impair
insulin action and induce apoptosis in a number of different cell
types and evidence exists in the literature implicating ceramide in
b-cell dysfunction. To test whether ceramide may be an effector
molecule mediating the lipid-induced loss in GSIS in MIN6 b cells
we investigated the effect of two inhibitors that suppress de novo
ceramide synthesis, AZ422 and fenretinide. AZ422 inhibits the
activity of SPT (Figure S1) and fenretinide suppresses the
conversion of dihydroceramide to ceramide by inhibiting dihy-
droceramide desaturase. Both inhibitors failed to antagonise the
palmitate-induced loss in GSIS indicating that any increase in
ceramide synthesis was unlikely to account for the impaired
secretion of insulin in response to palmitate (Figure 3A). Consistent
with this proposition, raising cell ceramide content by incubating
MIN6 b cells with increasing concentrations of C2-ceramide (a
short-chain cell permeant ceramide analogue) did not alter GSIS
when compared to output of insulin from untreated cells or those
incubated with the inert C2-dihydroceramide analogue
(Figure 3B). Ceramide concentrations above 50mM were not used
as these proved cytotoxic. It is important to stress that whilst 50mM
C2-ceramide did not affect GSIS this concentration of ceramide
was effective in promoting phosphorylation/activation of atypical
PKCs (a known ceramide target), whereas the inactive C2-
dihydroceramide did not (Figure 3C). In both adipocytes and
muscle cells ceramide is a potent inhibitor of PKB/Akt activation
[30,31]. However, it is noteworthy that in MIN6 b cells activation
of PKB in response to GSIS was unaffected by cell incubation with
C2-ceramide (Figure 3D). Analysis of cell ceramide content
following a 48 h palmitate incubation unexpectedly revealed that
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palmitate in MIN6 b cells (Figure 3E). The DAG kinase assay
that we employed readily detected significant increases in cell
ceramide following cell treatment with C2-ceramide (Figure 3E)
and in palmitate-driven DAG synthesis (Figure 3F). Incubation
with C2-dihyrdoceramide did not register any increase in
ceramide consistent with the fact that it does not serve as a
substrate for DAG kinase (Figure 3E).
Effects of palmitate on autocrine insulin signalling in
MIN6 b cells
The effect of palmitate on insulin signalling was subsequently
investigated in MIN6 b cells. Under conditions of low (3 mM) glucose
the phosphorylation of PKB and that of ERK1 and ERK2 was not
readily detectable, but was enhanced significantly upon incubation of
MIN6 b cells with high (16 mM) glucose (Figure 4A and 4B). This
glucose-induced increase in PKB and ERK phosphorylation was
blunted significantly upon preincubation of MIN6 b cells with
palmitate (Figure 4A and 4B). To assess whether this palmitate-
induced loss in PKB and ERK phosphorylation was due to impaired
GSIS, insulin was added exogenously to the media bathing MIN6 b
cells in the absence and presence of palmitate. This experimental
approach revealed that palmitate was unable to blunt the activation of
PKB in response to exogenously added insulin (Figure 4A) and that the
impaired activation of PKB seen in response to high glucose was more
likely explained by the inhibitory effect of palmitate on insulin secretion
rather than insulin signalling per se. In striking contrast, exogenously
supplied insulin did not activate ERK and was unable to over-ride the
inhibitory effect of palmitate on glucose-stimulated ERK phosphory-
lation (Figure 4B). This latter observation clearly implies that glucose-
induced ERK activation is not reliant upon autocrine activation of
proximal insulin-signalling components and depends upon a mecha-
nism that is distinct from that promoting activation of PKB.
Activation of ERK and CaMKII is required to support
glucose- and amino acid-induced insulin secretion
The finding that palmitate blunts glucose-stimulated ERK
signalling and also induces an attendant reduction in insulin
secretion implies that activation of ERK may be required to
support stimulus-induced insulin secretion. To test this proposition
we assessed the effect of U0126, a selective inhibitor of the MEK-
ERK signalling cascade, upon both glucose- and amino acid-
induced ERK activation and insulin secretion. Figure 5A shows
that increased provision of glucose or amino acids induces
activation of ERK signalling, which was suppressed by coincuba-
tion of cells with U0126. Associated with this inhibition in ERK
activation by U0126 was a significant reduction (by up to 62%) in
insulin secretion from MIN6 b cells in response to increased
availability of both glucose and amino acids (Figure 5B).
Previous work has indicated that glucose-induced increases in
cytosolic calcium can activate the ERK pathway via stimulation of
CaMKII and that this activation occurs independently of Ras and
Raf [32]. We therefore assessed the effects of CaMKII inhibition
on both glucose-induced ERK activation and insulin secretion.
Figure 6A and 6B shows that KN-62, a CaMKII inhibitor,
antagonised both ERK activation and insulin secretion in response
to increased glucose and amino acid provision. The notion that
CaMKII may serve as an intermediary in the activation of ERK
signalling and GSIS is further strengthened by the observation that
phosphorylation/activation of CaMKII itself in response to
glucose and amino acids was reduced following palmitate
treatment (Figure 6C).
Figure 1. Palmitate induces a loss in glucose- and amino acid-stimulated insulin secretion. (A) MIN6 b cells were incubated with palmitate
(0.4 mM) for 48 h prior to incubation with glucose (3 mM or 16 mM) or with an amino acid/glucose mix (10 mM leucine and glutamine/3 mM
glucose) for 1 h. Glucose-stimulated insulin secretion (GSIS) and amino acid-stimulated insulin secretion (AASIS) were then assessed as described in
the methods. The net change in insulin secretion from 3 to 16 mM glucose or to 10 mM amino acid was analysed and graphed (B). Values are mean
6 SEM from 3 separate experiments. The asterisk signifies a significant difference from the appropriate control (P,0.05).
doi:10.1371/journal.pone.0025975.g001
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dependent upon fatty acid oxidation
To assess whether the suppressive effect of palmitate upon ERK
signalling and GSIS involves mitochondrial fatty acid metabolism
we investigated the effect of 2-bromopalmitate, a non-oxidisable
analogue of palmitate. Figure 7A shows that 2-bromopalmitate
proved just as effective as palmitate in suppressing GSIS and,
despite its lack of metabolism, was just as effective in suppressing
activation of ERK, PKB and CaMKII (Figure 7B). To further
substantiate that fatty acid oxidation was unlikely to be an
important determinant of the palmitate-induced loss in GSIS,
MIN6 b cells were incubated with either carnitine or etomoxir.
Figure 2. Effects of palmitate on MIN6 b cell number and apoptosis. MIN6 b cells were incubated in the absence or presence of palmitate
(0.4 mM) for 48 h prior to analysis of cell number by DAPI staining (A) or (B) caspase 3/7 activity (a proapoptotic marker). Three random visual fields
from duplicate samples were chosen (typical phase, DAPI stained and merged images are shown in panel A), and adherent cell number noted from
control or palmitate-treated cells following DAPI staining (A and B). Alternatively, following the fatty acid incubation period cells were incubated with
caspase 3/7 assay reagent and caspase 3/7 activity determined by luminescence as described in methods (B). In some experiments, cells that had
been pre-treated with palmitate (0.4 mM, 48 h) were subsequently incubated with glucose (16 mM) or with an amino acid/glucose mix (10 mM
leucine and glutamine/3 mM glucose) for 1 h prior to analysis of cell number by DAPI staining (C). Bar values are mean 6 SEM from 3 or 4 separate
experiments. The asterisk signifies a significant difference from the appropriate control value (P,0.05).
doi:10.1371/journal.pone.0025975.g002
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oxidation, whereas etomoxir targets carnitine palmitoyltransferase
I (CPT1) and blocks mitochondrial fatty acid oxidation. Figure 7C
shows that carnitine supplementation had no impact on
palmitate’s inhibitory effect on GSIS, whereas blocking mitochon-
drial fatty acid uptake using etomoxir caused a marginal
enhancement in palmitate’s repressive effect on GSIS.
Discussion
Sustained increases in circulating free fatty acids is an early
indicator of insulin resistance [33]. As with skeletal muscle and
other insulin sensitive tissues, pancreatic beta cells are susceptible
to the negative effects of fatty acid excess [34]. Whilst fatty acids
are essential for supporting GSIS, increased availability as seen in
Figure 3. The de novo ceramide synthesis pathway is not involved in the palmitate-induced loss in glucose-stimulated insulin
secretion. MIN6 bcells were incubated either with or without 10 mM AZ422 (a SPT inhibitor) or 5 mM fenretinide (an inhibitor of dihydroceramide desaturase)
(A) for 48 h or with varying concentrations of ceramide and dihydroceramide (B–F) for 2 h. Palmitate (0.4 mM) was present for 48 h where indicated. Glucose
was added for 1 h for analysis of GSIS (A and B). Alternatively, cells were either lysed for immunoblot analysis using antibodies against (C) PKCf/l
Thr410 and total
PKCf/l (used as loading control), (D) PKB
Ser473 and total PKB (as a loading control) or harvested and lipids extracted to assess (E) ceramide or (F) DAG content.
Bars represent mean 6 SEM of 3 experiments and asterisks signify a significant difference from the untreated control value (P,0.05).
doi:10.1371/journal.pone.0025975.g003
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characterised by a reduction in GSIS [7] and increased
susceptibility to lipoapoptosis [35]. An increase in long chain
CoAs and palmitate-derived lipids such as ceramide and DAG has
been demonstrated in b cells of diabetic rodent models [6].
Ceramide has been widely implicated as a pro-apoptotic agent and
given that it can be generated from palmitate, a plausible
hypothesis is that pancreatic b-cell dysfunction and apoptosis is
mediated by palmitate-driven ceramide synthesis. It thus follows
that suppressing cellular production of ceramide may potentially
have beneficial consequences with regard b cell function.
However, our analysis has revealed that whilst sustained provision
of palmitate impairs GSIS from MIN6 b cells the fatty acid does
not appear, under these circumstances, to drive an increase in
ceramide synthesis. MIN6 b cells express both subunits of serine
palmitoyl transferase (SPT) and whilst we find the enzyme is
competent in generating ceramide from palmitate in vitro (see
Figure S1) our observations indicate that ceramide is unlikely to be
a key effector underpinning the loss in GSIS in response to
palmitate in intact MIN6 b cells. The finding that inhibiting de novo
ceramide synthesis via SPT or indeed incubating cells with a cell
permeant ceramide analogue had no effect on GSIS would be
consistent with this proposition. Moreover, it is noteworthy that
our observations are fully in line with very recent studies in MIN6
cells in which sustained exposure to palmitate failed to induce
increases in intracellular ceramide synthesis [36] or in which
inhibition of de novo ceramide synthesis [37] did not attenuate the
inhibitory effect of palmitate on insulin secretion.
An important finding to emerge from our work is that, unlike
adipocytes and skeletal muscle cells [30,31], palmitate does not
impair insulin signalling in MIN6 b cells given that prior
incubation of cells with palmitate had no detectable effect on
activation of PKB signalling in response to exogenously added
insulin. In both fat and muscle cells the loss in insulin-signalling
capacity associated with palmitate supply is mechanistically
attributed to ceramide generated from the fatty acid [30,31].
However, such a mechanism appears not to operate in MIN6 b
cells based on the finding that C2-ceramide does not inhibit PKB
activation in response to a raised glucose stimulus, which invokes
GSIS and autocrine signalling by insulin in these cells. Although
C2-ceramide appears not to modulate GSIS in our hands, recent
work has suggested that the lipid does inhibit glucose-induced
insulin gene expression in MIN6 b cells [38]. It is therefore
possible that the effects of ceramide may be selectively targeted at
insulin gene expression rather than hormone secretion, but given
that we detect very little de novo synthesis of ceramide from
palmitate the importance of such regulation may only become
germane if the lipid is generated in significant amounts via other
routes involving, for example, upregulation in the activity of
membrane bound sphingomyelinases [39].
Whilst insulin is a very poor stimulus for inducing ERK
activation in MIN6 b cells, cell incubation with high glucose
(16 mM) leads to a robust activation/phosphorylation of ERK.
Our findings indicate that activation of ERK signalling is
important for supporting efficient GSIS/AASIS based on
sensitivity to the MEK inhibitor, U0126. This inhibitor has been
reported to promote activation of AMPK in HEK293 cells and so
it is plausible the drug-induced reduction in GSIS/AASIS may be
due to AMPK-mediated antagonism [40]. However, we believe
this is highly unlikely given that U0126 has no direct effect on
AMPK activity in cell-free assays [41] and does not promote any
detectable increase in phosphorylation of acetyl CoA carboxylase,
a physiological downstream AMPK substrate in MIN6 cells (data
not shown).
Previous work has shown that the sequalae of events that follow
uptake and metabolism of glucose (i.e. increased cytoplasmic
ATP/ADP ratio, closure of ATP-sensitive K
+ channels, depolar-
ization of the cell membrane, opening of voltage-gated calcium
channels and the subsequent influx of extracellular calcium into
the cell) induces activation of CaMKII, which acts upstream of
MEK1/2 to mediate ERK phosphorylation [32,42]. ERK
activation in turn has been reported to promote cytoskeletal
rearrangement [43] and phosphorylation of cytoplasmic proteins
implicated in exocytosis of insulin granules, such as synapsin I
[44]. However, under conditions when b cells are chronically
exposed to an elevated supply of palmitate the glucose-induced
activation of ERK is significantly blunted. We believe that the
reduced activation of ERK is likely to be a consequence of an
associated reduction in CaMKII signalling. This belief is based not
Figure 4. Palmitate does not inhibit PKB activation in response
to exogenously added insulin but does prevent glucose-
induced activation of ERK. MIN6 b cells were incubated in the
absence or presence of palmitate (0.4 mM) for 48 h. Glucose (16 mM)
was added for 1 h and insulin (100 nM) in the penultimate 10 min of
this incubation period. Cells were harvested and immunoblotted for
phospho-PKB
Ser473 (A) and phospho-ERK
Thr202/Tyr204 (B) and normalised
against total protein. Bars represent mean 6 SEM from 3 separate
experiments and asterisks signify a significant difference from the
untreated control values (P,0.05).
doi:10.1371/journal.pone.0025975.g004
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activation of CaMKII, but the observation that, even in cells not
exposed to the fatty acid, CaMKII inhibition with KN-62
suppresses activation of ERK in response to a raised glucose
stimulus. Moreover, consistent with the idea that CaMKII-
directed signaling is important for promoting insulin secretion
we find that KN-62 causes a significant reduction in GSIS. In
addition to glucose, certain amino acids are also potent insulin
secretagogues being able to induce hormone secretion as a
consequence of their capacity to depolarise the b-cell membrane
and cause the concomitant opening of voltage-gated calcium
channels. Membrane depolarisation may be triggered directly by
some amino acids (e.g. arginine), whereas others (e.g. alanine,
glutamine, leucine) may induce it via a combination of their influx
into b-cells via Na-coupled amino acid transporters and/or
metabolism that enhances ATP generation with subsequent effects
upon K-ATP channels in much the same manner as glucose [45].
Given that the effects of glucose and amino acids converge upon
regulation of a common plasma membrane channel it is perhaps
not unsurprising that sustained exposure of MIN6 b cells to
palmitate also results in impaired downstream activation of
CaMKII and ERK in response to amino acid provision.
A key issue of interest is the mechanism by which over supply of
palmitate induces impaired GSIS. Since metabolism of glucose
and the associated increase in cytoplasmic ATP/ADP ratio is
central for stimulus-secretion coupling in b-cells it is plausible that
palmitate may reduce glucose metabolism and thereby limit GSIS.
However, previous work has shown that sustained (72 h)
incubation of MIN6 b cells with palmitate does not affect
glycolytic flux or ATP synthesis [46] negating this as a likely
possibility. It also appears unlikely that oxidation of palmitate itself
is required for initiating the reduction in GSIS. Etomoxir, which
inhibits mitochondrial fatty acid uptake via CPT1, failed to prevent
the reduction in GSIS, whereas carnitine supplementation, which
would promote mitochondrial fatty acid uptake/oxidation [47],
did not augment the palmitate-induced loss in insulin secretion.
Furthermore, the finding that 2-bromopalmitate, which cannot
undergo mitochondrial oxidation, was as potent as palmitate in
suppressing GSIS underscores the notion that changes in
mitochondrial fatty acid oxidation are unlikely to account for
the observed reduction in GSIS. This latter observation is also in
line with work assessing the inhibitory effect of palmitate on
glucose-induced insulin gene expression in b cells in which 2-
bromopalmitate was found to mimic the repressive effect of
palmitate and in which fatty acid esterification rather than
oxidation was deemed as the more important determinant of
palmitate-induced lipotoxicity [48]. Consistent with this suggestion
we did observe that the repressive effect of palmitate upon GSIS
was further enhanced in the presence of etomoxir, which may
promote greater partitioning of palmitate into pathways favouring
its esterification to diacylglycerol (DAG) and triglyceride. While we
did not detect significant generation of ceramide from palmitate in
Figure 5. ERK inhibition induces a loss in glucose-stimulated insulin secretion (GSIS) and amino acid-stimulated insulin secretion
(AASIS). MIN6 b cells were incubated in the absence or presence of 20 mM U0126, as indicated prior to being exposed to either 3 mM or 16 mM
glucose for 1 h or alternatively to an amino acid stimulus (10 mM leucine/glutamine and 3 mM glucose). At the end of this incubation cells were (A)
lysed for analysis of ERK phosphorylation in whole cell lysates or (B) prepared for analysis of net changes in GSIS or AASIS (B) as described in methods.
Bars represent mean 6 SEM from 3 separate experiments and asterisks signify a significant difference from the untreated control values (P,0.05).
doi:10.1371/journal.pone.0025975.g005
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treated MIN6 b cells. An increase in intracellular DAG would be
expected to promote activation of DAG-sensitive PKCs, which are
thought to mediate the effects of acute increases in fatty acid
provision upon numerous aspects of b-cell function, including
potentiation of GSIS [49]. However, it is plausible that sustained
fatty acid overload may result in synthesis and accumulation of
distinct DAG species and/or activation of specific PKC isoforms
that are potentially pathogenic in nature. Cantley and coworkers
have suggested that PKCe may contribute to impaired GSIS given
that its deletion in mouse b-cells induces amplification of pathways
stimulating GSIS in isolated islets cultured chronically in the
presence of palmitate [50]. Whilst the increase in GSIS induced in
PKCe knock-out islets was suggested to operate independently of
any changes in intracellular calcium, very recent work has
reported that sustained exposure of islets to palmitate impairs
calcium influx at membrane domains that are in close proximity to
insulin granules with a consequential reduction in their exocytosis
[51]. Using a fluorescent calcium indicator dye, Oregon-Green-
BAPTA-1, we find that glucose induces calcium transients in
MIN6 b cells and that these are muted in cells that have been
chronically pre-exposed to palmitate for 48 hours (see Figure S2).
It is plausible that these calcium transients may normally support
the activation of CaMKII and that their reduction impairs efficient
Figure 6. Palmitate antagonises the stimulus-induced activation of ERK and CaMKII in MIN6 b cells. MIN6 b cells were incubated with
10 mM KN62 (an inhibitor of CaMKII) for 2 h. In the last hour of this incubation cells were incubated with either glucose (16 mM) or amino acids
(10 mM) prior to assessing (A) GSIS or AASIS, (B) ERK activation by analysis of ERK
Thr202/Tyr204 phosphorylation. Total ERK content was used for
assaying protein loading. Alternatively, MIN6 b cells were incubated in the absence or presence of palmitate (0.4 mM) for 48 h and then stimulated
insulin secretion assessed by the addition of glucose or amino acids for 1 h at the concentrations indicated. Cells were lysed and lysates
immunoblotted to assay phospho-CaMKII
Thr286 phosphorylation with native CaMKII serving as a gel loading control (C). Bars represent mean 6 SEM
from 3 separate experiments and asterisks signify a significant difference from the untreated control values (P,0.05).
doi:10.1371/journal.pone.0025975.g006
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downstream targets involved in the insulin secretory process.
Testing this latter possibility represents an important investigative
goal of future work.
In summary, whilst the lipotoxic effects of fatty acid over load
will undoubtedly promote metabolic (endoplasmic reticulum and
oxidative) stress and reduce the insulin secretion capacity of beta
cells via activation of pro-apoptotic pathways [45], our studies
indicate that insulin secretion from MIN6 b cells in response to
glucose or amino acids is critically dependent upon the nutrient-
induced activation of CaMKII and ERK. Sustained exposure of
MIN6 b cells to palmitate results in impaired activation of both
signalling molecules with an attendant reduction in insulin
secretion. While there is no suggestion from our work that the
Figure 7. The repressive effects of palmitate on glucose-stimulated insulin secretion, PKB and ERK activation are not dependent
upon fatty acid oxidation. (A) MIN6 b cells were incubated with varying concentrations of palmitate and 2-bromopalmitate (48 h) as indicated.
Glucose (16 mM) was added for 1 h during serum starvation and the net change in glucose-stimulated insulin secretion assessed. (B) Cells were
incubated in the absence or presence of 0.4 mM 2-bromopalmitate for 48 h and with glucose at the indicated concentration for 1 h. Cells were lysed
and lysates immunoblotted for analysis of ERK
Thr202/Tyr204, PKB
Ser473, CaMKII
Thr286 and total PKB, ERK and CaMKII. (C) Cells were incubated in the
absence or presence of palmitate (0.4 mM) for 48 h and then after serum starvation cells were exposed to either L-carnitine (1 mM) or etomoxir
(0.2 mM) for 2 h as indicated. Glucose (16 mM) was added during the final hour to induce GSIS and media removed for analysis of insulin content.
Bars represent mean 6 SEM from 3 separate experiments and asterisks or a cross signify a significant difference from the untreated control values or
between indicated bars (P,0.05).
doi:10.1371/journal.pone.0025975.g007
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acid-derived ceramide synthesis or fatty acid oxidation, the loss in
stimulus-secretion coupling may involve a targeted disruption in
calcium influx via voltage-dependent calcium channels in response
to increased esterification/synthesis of fatty acid-derived metabo-
lites such as DAG.
Methods
Reagents and antibodies
Dulbeccos Modified Eagle Medium (DMEM), foetal bovine
serum (FBS), Trypsin/EDTA solution and penicillin/streptomycin
solution (containing penicillin G sodium (10,000 unit/ml),
streptomycin sulphate (10,000 mg/ml) in 0.85% saline) were
purchased from Gibco/Invitrogen Life Technologies (Paisley,
UK). Other reagent grade chemicals were purchased from Sigma-
Aldrich (Poole, UK). This included insulin, palmitate, C2-
dihydroceramide, fenretinide, 2-bromopalmitate, dimethyl sulph-
oxide (DMSO), 4,6-diamino-2-phenylindole diacetate (DAPI) and
anti-actin. Bovine Serum Albumin (BSA) for conjugating palmitate
and complete protein phosphatases inhibitor tablets were pur-
chased from Boehringer-Roche Diagnostics (Basel, Switzerland).
The Caspase-Glo 3/7 assay kit for apoptosis analysis was
purchased from Promega (Southampton, UK). The ELISA
(Enzyme-Linked ImmunoSorbent Assay) kit for insulin detection
in MIN6 b cells was from Mercodia (Uppsala, Sweden). C2-
ceramide was purchased from Tocris (Bristol, UK). Antibodies to
Protein Kinase B (PKB)/Akt, PKB/Akt phospho-Ser
473 ERK
phospho-Thr
202/Tyr
204, CaMKII phospho-Thr
286 and CaMKII
were purchased from New England Biolabs (Herts, UK) whilst
that to atypical PKC l/f was from Santa Cruz (California, USA).
The inhibitor AZ422 was synthesised and kindly supplied by Astra
Zeneca (Cheshire, UK).
Cell culture
MIN6 b cells were grown to 80–90% confluence in Dulbecco’s
Modified Eagle Medium (DMEM) containing 10% (v/v) FBS, 1%
(v/v) penicillin/streptomycin. Cells were incubated for periods and
with the appropriate effectors as indicated in the figure legends.
Following appropriate incubation cells were washed twice with ice
cold phosphate-buffered saline (PBS) prior to lysis in buffer
containing 50 mM TRIS pH 7.4, 0.27 M sucrose, 1 mM Na-
Orthovanodate pH 10, 1 mM EDTA 1 mM EGTA, 10 mM Na-
b-glycerophosphate, 50 mM NaF, 5 mM Na-pyrophosphate, 1%
(v/v) Triton X-100, 0.1% 2-mercaptoethanol and protease
inhibitors. Whole cell lysates were centrifuged at 4000 g,4 uC for
10 min and stored at 220uC after being snap frozen in liquid
nitrogen.
Analysis of insulin release
MIN6 b cells were serum starved for 1 h in Krebs Ringer Hepes
(KRH) buffer (10 mM Hepes, pH 7.4, 129 mM NaCl, 5 mM
NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4,
2.5 mM CaCl2 and 0.1% (w/v) BSA) prior to the addition of
KRH buffer+glucose (3 or 16 mM) or an amino acid mix
containing a nominal amount of glucose (3 mM glucose, 10 mM
leucine and glutamine) for a further 1 h before analysis. After
appropriate cell incubations and stimulation, 100 ml of the
supernatant was removed and transferred into two fresh 96 well
plates. The media was then diluted 1:40 with KRH buffer (without
BSA) and analysed for insulin content using an insulin ELISA kit.
Unknown samples were calculated from a standard curve
generated from known insulin standards supplied with the kit.
Caspase-Glo 3/7 assay
Apoptosis was assessed using a Caspase-Glo 3/7 assay kit from
Promega. MIN6 b cells were seeded into a white-walled 96-well
plate and incubated with the appropriate effectors. Cells were
washed and 100 ml of serum free DMEM media added to each
well. The Caspase-Glo substrate and buffer were mixed together
thoroughly and 100 ml was then added to each well and left for up
to 3 h. The luminescence generated by the assay is proportional to
the amount of caspase activity present, allowing quantification of
apoptotic activity.
Analysis of cellular ceramide and DAG content
After appropriate cell treatments, MIN6 b cells were extracted
from plates using a rubber policeman in ice-cold PBS for analysis
of ceramide and DAG using the DAG kinase method that relies on
the kinase catalysing the formation of ceramide 1-phosphate and
phosphatidic acid, respectively. Briefly, lipids were extracted from
a cell aliquot containing 400 mg protein by the addition of
chloroform/methanol (1:2, v/v) with the phases being broken by
the addition of chloroform and 1 M NaCl. The organic phase was
separated, dried and used as substrate for the DAG kinase assay
for measurement of ceramide and DAG content as described
previously [52].
SDS-PAGE and immunoblotting
Cell lysates (30–50 mg protein) were reconstituted in Laemmli
buffer and subjected to SDS-PAGE on 10% resolving gels and
transferred onto immobilon-P membranes as described previously
[53]. Membranes were probed with primary antibodies of interest
and subsequently detected using either horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG or anti-mouse-IgG (New
England Biolabs). Membranes were visualized using enhanced
chemiluminescence (Pierce, Northumberland, UK) on Konica
Minolta x-ray medical film (Staffordshire, UK).
49-6-Diamidino-2-phenylindole (DAPI) staining of cell
nuclei
Cells were seeded onto 0.1 mm coverslips placed in a 6 well plate,
and incubated with palmitate for times and at concentrations indicated
in the figure legends. After the appropriate period of incubation with
palmitate cells were washed three times with PBS. Cells were fixed by
addition of 4% (w/v) paraformaldehyde (PFA) and left for 10 min. The
PFA was removed and fixed cells washed three times with PBS before
addition of 100 mM glycine for 15 min. The fixed cells were washed
again with PBS three times and incubated with 50 mlo fad i l u t e dD A P I
stock (10 mg/ml) for 15 min. The coverslips were then washed a
further three times with PBS and mounted onto microscope slides.
DAPI fluorescence was viewed and images captured using an inverted
fluorescence microscope (Leica DM IRB, Leica, UK). Individual
nuclei of adherent cells from randomly selected fields of view were
counted from at least three separate experiments.
Statistical analysis
One way analysis of variance (ANOVA) followed by a Newman-
Keuls post test, was used to analyse statistical significance. Data
analysis was performed using GraphPad prism software and
considered statistically significant at values of P,0.05.
Supporting Information
Figure S1 SPT is expressed in MIN6b cells and its
activity is sensitive to AZ422. MIN6b cells were incubated in
the absence and presence of 10 mM AZ422 for 48 h. Cells were
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were immunoblotted for SPT-LCB1, SPT-LCB2 and the a1
subunit of Na/K ATPase for total protein. The blot confirms the
expression of SPT within MIN6b cells. (B) In vitro SPT activity was
analysed as described previously [28]. Briefly, 80 mg of total
membranes were taken and the SPT reaction buffer added
(100 mM HEPES pH 8.3, 2.5 mM EDTA pH 7.0, 5 mM DTT,
50 mM Pyridaoxal Phosphate, 1 mM serine, 1 mCi [
3H]-serine/
reaction and 10 mM AZ422 where indicated). Addition of
palmitoyl-CoA initiated the assay (H2O substituted for palmitoyl-
CoA in the control background sample). The reaction was allowed
to proceed for10 minat 37uC and terminatedby the additionof 0.5
NN H 4OH. Lipids were extracted using chloroform/methanol
added to break the phases. NH4OH and sphinganine was added to
act as a carrier for the lipid product generated. The resulting
mixture was vortexed thoroughly and centrifuged. The upper
aqueous phase was carefully removed and the lower organic phase,
which contained the lipid products was washed twice with H2O.
About 50–70% of the organic phase was vacuum-dried and the
dried lipids reconstituted in 6.5:1:1 (v/v/v) chloroform/methanol/
acetic acid and radioactivity assessed. Bars represent mean 6 SEM
from 3 separate experiments the asterisk signifies a significant
difference between the indicated bars (P,0.05).
(PDF)
Figure S2 Palmitate inhibits glucose-induced calcium
oscillations. MIN6 b cells were incubated with 0.4 mM
palmitate for 48 h. Glucose was then added for 1 h for stimulation
before assessment of calcium content. Briefly, during the 1 h
glucose stimulation, cells were also incubated with 5 mM Oregon
Green Bapta-1 probe (Molecular Probes, Invitrogen). After 1 h
cells were washed 36with KRH buffer and then viewed using a
fluorescence microscope. Movies were taken over a 2–3 min time
period but only the first 12 seconds are shown here to simplify the
graph. Each time point is the average of 7 different cells but the
error bars were removed, again for ease of view. Area under the
curve analysis for each of the three conditions shown in the figure
was performed using GraphPad prism and this analysis is
presented in the table.
(PDF)
Author Contributions
Conceived and designed the experiments: MW HH. Performed the
experiments: MW KM. Analyzed the data: MW KM AM HH.
Contributed reagents/materials/analysis tools: AM. Wrote the paper:
MW HH. Contributed to the intellectual content/editing of the paper:
MW AM HH.
References
1. Corcoran MP, Lamon-Fava S, Fielding RA (2007) Skeletal muscle lipid
deposition and insulin resistance: effect of dietary fatty acids and exercise.
Am J Clin Nutr 85: 662–677.
2. Tuunanen H, Ukkonen H, Knuuti J (2008) Myocardial fatty acid metabolism
and cardiac performance in heart failure. Curr Cardiol Rep 10: 142–148.
3. Anderwald C, Brunmair B, Stadlbauer K, Krebs M, Furnsinn C, et al. (2007)
Effects of free fatty acids on carbohydrate metabolism and insulin signalling in
perfused rat liver. Eur J Clin Invest 37: 774–782.
4. Gertow K, Rosell M, Sjogren P, Eriksson P, Vessby B, et al. (2006) Fatty acid
handling protein expression in adipose tissue, fatty acid composition of adipose
tissue and serum, and markers of insulin resistance. Eur J Clin Nutr 60:
1406–1413.
5. Unger RH, Zhou YT (2001) Lipotoxicity of beta-cells in obesity and in other
causes of fatty acid spillover. Diabetes 50 Suppl 1: S118–S121.
6. Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced beta
cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95:
2498–2502.
7. Biden TJ, Robinson D, Cordery D, Hughes WE, Busch AK (2004) Chronic
effects of fatty acids on pancreatic beta-cell function: new insights from
functional genomics. Diabetes 53 Suppl 1: S159–S165.
8. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, et al. (1996)
Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in
the fasted rat. J Clin Invest 97: 2728–2735.
9. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M (2006)
Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 55 Suppl 2:
S16–S23.
10. Nolan CJ, Prentki M (2008) The islet beta-cell: fuel responsive and vulnerable.
Trends Endocrinol Metab 19: 285–291.
11. Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, et al. (2004) A role for the
malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation
of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 53:
1007–1019.
12. Brun T, Roche E, Assimacopoulos-Jeannet F, Corkey BE, Kim KH, et al. (1996)
Evidence for an anaplerotic/malonyl-CoA pathway in pancreatic beta-cell
nutrient signaling. Diabetes 45: 190–198.
13. Prentki M, Corkey BE (1996) Are the beta-cell signaling molecules malonyl-CoA
and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity
and NIDDM? Diabetes 45: 273–283.
14. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, et al. (2007) GPR40 is
necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo.
Diabetes 56: 1087–1094.
15. Kwan EP, Xie L, Sheu L, Nolan CJ, Prentki M, et al. (2006) Munc13-1
deficiency reduces insulin secretion and causes abnormal glucose tolerance.
Diabetes 55: 1421–1429.
16. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, et al. (2002) Prolonged
exposure to free fatty acids has cytostatic and pro-apoptotic effects on human
pancreatic islets: evidence that beta-cell death is caspase mediated, partially
dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51: 1437–1442.
17. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY (2003)
Monounsaturated fatty acids prevent the deleterious effects of palmitate and
high glucose on human pancreatic beta-cell turnover and function. Diabetes 52:
726–733.
18. Zhou YP, Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty
acids inhibits glucose-induced insulin secretion and biosynthesis through a
glucose fatty acid cycle. J Clin Invest 93: 870–876.
19. Bollheimer LC, Skelly RH, Chester MW, McGarry JD, Rhodes CJ (1998)
Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content
by increasing basal insulin secretion that is not compensated for by a
corresponding increase in proinsulin biosynthesis translation. J Clin Invest
101: 1094–1101.
20. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, et al. (1995) A
high concentration of fasting plasma non-esterified fatty acids is a risk factor for
the development of NIDDM. Diabetologia 38: 1213–1217.
21. Zhou YP, Grill VE (1995) Palmitate-induced beta-cell insensitivity to glucose is
coupled to decreased pyruvate dehydrogenase activity and enhanced kinase
activity in rat pancreatic islets. Diabetes 44: 394–399.
22. Assimacopoulos-Jeannet F, Thumelin S, Roche E, Esser V, McGarry JD, et al.
(1997) Fatty acids rapidly induce the carnitine palmitoyltransferase I gene in the
pancreatic beta-cell line INS-1. J Biol Chem 272: 1659–1664.
23. Brun T, Assimacopoulos-Jeannet F, Corkey BE, Prentki M (1997) Long-chain
fatty acids inhibit acetyl-CoA carboxylase gene expression in the pancreatic
beta-cell line INS-1. Diabetes 46: 393–400.
24. Hagman DK, Hays LB, Parazzoli SD, Poitout V (2005) Palmitate inhibits insulin
gene expression by altering PDX-1 nuclear localization and reducing MafA
expression in isolated rat islets of Langerhans. J Biol Chem 280: 32413–32418.
25. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, et al. (2001) Effects of
free fatty acids on beta-cell functions: a possible involvement of peroxisome
proliferator-activated receptors alpha or pancreatic/duodenal homeobox.
Metabolism 50: 613–618.
26. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, et al. (1998)
Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine
palmitoyltransferase overexpression. J Biol Chem 273: 32487–32490.
27. Kelpe CL, Moore PC, Parazzoli SD, Wicksteed B, Rhodes CJ, et al. (2003)
Palmitate inhibition of insulin gene expression is mediated at the transcriptional
level via ceramide synthesis. J Biol Chem 278: 30015–30021.
28. McGarry JD, Dobbins RL (1999) Fatty acids, lipotoxicity and insulin secretion.
Diabetologia 42: 128–138.
29. Thorens B (2003) A gene knockout approach in mice to identify glucose sensors
controlling glucose homeostasis. Pflugers Arch 445: 482–490.
30. Chavez JA, Summers SA (2003) Characterizing the effects of saturated fatty
acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-
L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 419: 101–109.
31. Powell DJ, Turban S, Gray A, Hajduch E, Hundal HS (2004) Intracellular
ceramide synthesis and protein kinase Czeta activation play an essential role in
palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J
382: 619–629.
Palmitate and Beta Cell Insulin Secretion
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e2597532. Gomez E, Pritchard C, Herbert TP (2002) cAMP-dependent protein kinase and
Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-
independent activation of extracellular regulated kinase in response to glucagon-
like peptide-1 in pancreatic beta-cells. J Biol Chem 277: 48146–48151.
33. Beha A, Juretschke HP, Kuhlmann J, Neumann-Haefelin C, Belz U, et al. (2006)
Muscle type-specific fatty acid metabolism in insulin resistance: an integrated in
vivo study in Zucker diabetic fatty rats. Am J Physiol 290: E989–E997.
34. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:
473–481.
35. Kharroubi I, Ladriere L, Cardozo AK, Dogusan Z, Cnop M, et al. (2004) Free
fatty acids and cytokines induce pancreatic beta-cell apoptosis by different
mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress.
Endocrinology 145: 5087–5096.
36. Boslem E, MacIntosh G, Preston AM, Bartley C, Busch AK, et al. (2011) A
lipidomic screen of palmitate-treated MIN6 beta-cells links sphingolipid
metabolites with endoplasmic reticulum (ER) stress and impaired protein
trafficking. Biochem J 435: 267–276.
37. Thorn K, Bergsten P (2010) Fatty acid-induced oxidation and triglyceride
formation is higher in insulin-producing MIN6 cells exposed to oleate compared
to palmitate. J Cell Biochem 111: 497–507.
38. Fontes G, Semache M, Hagman DK, Tremblay C, Shah R, et al. (2009)
Involvement of Per-Arnt-Sim Kinase and extracellular-regulated kinases-1/2 in
palmitate inhibition of insulin gene expression in pancreatic beta-cells. Diabetes
58: 2048–2058.
39. Marchesini N, Hannun YA (2004) Acid and neutral sphingomyelinases: roles
and mechanisms of regulation. Biochem Cell Biol 82: 27–44.
40. Da S, X, Leclerc I, Varadi A, Tsuboi T, Moule SK, et al. (2003) Role for AMP-
activated protein kinase in glucose-stimulated insulin secretion and preproinsulin
gene expression. Biochem J 371: 761–774.
41. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of
protein kinase inhibitors: a further update. Biochem J 408: 297–315.
42. Benes C, Poitout V, Marie JC, Martin-Perez J, Roisin MP, et al. (1999) Mode of
regulation of the extracellular signal-regulated kinases in the pancreatic beta-cell
line MIN6 and their implication in the regulation of insulin gene transcription.
Biochem J 340(Pt 1): 219–225.
43. Kowluru A, Veluthakal R, Rhodes CJ, Kamath V, Syed I, et al. (2010) Protein
farnesylation-dependent Raf/extracellular signal-related kinase signaling links to
cytoskeletal remodeling to facilitate glucose-induced insulin secretion in
pancreatic beta-cells. Diabetes 59: 967–977.
44. Longuet C, Broca C, Costes S, Hani EH, Bataille D, et al. (2005) Extracellularly
regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phosphorylate
synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of
Langerhans. Endocrinology 146: 643–654.
45. Newsholme P, Gaudel C, McClenaghan NH (2010) Nutrient Regulation of
Insulin Secretion and beta-Cell Functional Integrity. Adv Exp Med Biol 654:
91–114.
46. Iizuka K, Nakajima H, Namba M, Miyagawa J, Miyazaki J, et al. (2002)
Metabolic consequence of long-term exposure of pancreatic beta cells to free
fatty acid with special reference to glucose insensitivity. Biochim Biophys Acta
1586: 23–31.
47. Mynatt RL (2009) Carnitine and type 2 diabetes. Diabetes Metab Res Rev 25
Suppl 1: S45–S49.
48. Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V (2001) Lipotoxicity of the
pancreatic beta-cell is associated with glucose-dependent esterification of fatty
acids into neutral lipids. Diabetes 50: 315–321.
49. Biden TJ, Schmitz-Peiffer C, Burchfield JG, Gurisik E, Cantley J, et al. (2008)
The diverse roles of protein kinase C in pancreatic beta-cell function. Biochem
Soc Trans 36: 916–919.
50. Cantley J, Burchfield JG, Pearson GL, Schmitz-Peiffer C, Leitges M, et al. (2009)
Deletion of PKCepsilon selectively enhances the amplifying pathways of glucose-
stimulated insulin secretion via increased lipolysis in mouse beta-cells. Diabetes
58: 1826–1834.
51. Hoppa MB, Collins S, Ramracheya R, Hodson L, Amisten S, et al. (2009)
Chronic palmitate exposure inhibits insulin secretion by dissociation of Ca(2+)
channels from secretory granules. Cell Metab 10: 455–465.
52. Watson ML, Coghlan M, Hundal HS (2009) Modulating serine palmitoyl
transferase (SPT) expression and activity unveils a crucial role in lipid-induced
insulin resistance in rat skeletal muscle cells. Biochem J 417: 791–801.
53. Hajduch E, Alessi DR, Hemmings BA, Hundal HS (1998) Constitutive
activation of Protein Kinase Ba (PKBa) by membrane targeting promotes
glucose and System A amino acid transport, protein synthesis and GSK3
inactivation in L6 muscle cells. Diabetes 47: 1006–1013.
Palmitate and Beta Cell Insulin Secretion
PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e25975